DOCSLIB.ORG

Antimicrobial Susceptibility Testing Discs Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimicrobial Susceptibility Testing Discs Product List ANTIMICROBIAL SUSCEPTIBILITY TESTING DISCS (ASTD) PRODUCT LIST 2020 PRODUCT LIST 2020/01 PRODUCT LIST 2020/01 Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg ASD07702 Polymixin B PB 50 U ASD08601 Sulphamethoxazole SMZ 50 ASD09411 Vancomycin VA 10 AUXILIARY PRODUCTS A ASD01200 Cefamandole MA 30 ASD07701 Polymixin B PB 100 U ASD08600 Sulphamethoxazole SMZ 100 ASD09400 Vancomycin VA 30 ASD10011 Blank Disc in Cartridge BLK/CR --- ASD00110 Amikacin AK 10 ASD01300 Cefazolin CZ 30 ASD07700 Polymixin B PB 300 U ASD08603 Sulphamethoxazole SMZ 200 ASD09412 Vancomycin VA 120 ZON40300 Illuminator ZON --- ASD00100 Amikacin AK 30 ASD01340 Cefdinir CD 5 ASD07740 Pristinamycin PT 15 ASD08604 Sulphamethoxazole SMZ 300 ASD09450 Virginamycin VIR 15 TRG40200 Trigger (single dispenser) TRG --- ASD00300 Aminosidin AN 60 ASD01341 Cefdinir CD 30 ASD07730 Prulifloxacin ULI 5 T X + V DSP41100 Dispenser (8 Magazine) DSP-8 --- ASD00402 Amoxicillin AX 2 ASD01342 Cefdinir CD 50 ASD07750 PYR PYR --- ASD09110 Ticarcillin/clavulanic acid TIM 85 ASD09600 X factor disc X --- DSP42100 Dispenser (6 Magazine) DSP-6 --- ASD00410 Amoxicillin AX 10 ASD01360 Cefditoren CDN 5 STR00100 PYR Strip PYR/S --- ASD09150 Tigecycline TGC 15 ASD09610 V factor disc V --- ASD00403 Amoxicillin AX 20 ASD01405 Cefepime FEP 5 * The “Antifungal Discs” given above are also included into this list R ASD08700 Teicoplanin TEC 30 ASD09620 X + V factor disc X + V --- alphabetically. ASD00400 Amoxicillin AX 25 ASD01410 Cefepime FEP 10 ASD07805 Rifampin (Rifampicin) RA 1 ASD08701 Teicoplanin/Norfloxacin TCN 40 ANTIFUNGAL DISCS ASD00401 Amoxicillin AX 30 ASD01400 Cefepime FEP 30 ASD07810 Rifampin (Rifampicin) RA 2 ASD08800 Telithromycin TEL 15 ASD00451 Amphotericin B AMB 20 U ASD00430 Amoxicillin/clavulanic acid AMC 3 ASD01431 Cefepime/clavulanic acid FEC 15 ASD07800 Rifampin (Rifampicin) RA 5 ASD08825 Temocillin TEM 30 ASD00450 Amphotericin B AMB 100 U ASD00420 Amoxicillin/clavulanic acid AMC 30 ASD01430 Cefepime/clavulanic acid FEC 40 ASD07801 Rifampin (Rifampicin) RA 15 ASD08905 Tetracycline TE 5 ASD00915 Caspofungin CAS 5 ASD00240 Ampicillin AM 2 ASD01500 Cefixime CFM 5 ASD07820 Rifampin (Rifampicin) RA 30 ASD08910 Tetracycline TE 10 ASD03181 Clotrimazole CLT 10 ASD00200 Ampicillin AM 10 ASD01501 Cefixime CFM 10 ASD08001 Roxithromycin ROX 15 ASD08911 Tetracycline TE 25 ASD03183 Clotrimazole CLT 20 ASD00210 Ampicillin AM 20 ASD01502 Cefixime CFM 30 ASD08000 Roxithromycin ROX 30 ASD08900 Tetracycline TE 30 ASD03182 Clotrimazole CLT 50 ASD00220 Ampicillin AM 25 ASD01503 Cefixime/clavulanic acid CXC 15 S ASD09000 Thiamphenicol TP 30 ASD03180 Clotrimazole CLT 300 ASD00230 Ampicillin AM 30 ASD01504 Cefixime/clavulanic acid CXC 40 ASD08060 Sodium polyanethol sulfonate SPS --- ASD09005 Tiamulin TIA 30 ASD03460 Econazole ECO 10 ASD00252 Ampicillin/dicloxacillin AMD 11 ASD01505 Cefmetazole CMZ 30 ASD08100 Sparfloxacin SPX 5 ASD09006 Tiamulin TIA 50 ASD03461 Econazole ECO 50 ASD00250 Ampicillin/cloxacillin APX 30 ASD01600 Cefodizime CDZ 30 ASD08110 Sparfloxacin SPX 10 ASD09100 Ticarcillin TIC 75 ASD03931 Fluconazole FLU 10 ASD00240 Ampicillin/sulbactam SAM 20 ASD01660 Cefonicid CID 30 ASD08210 Spectinomycin SPT 10 ASD09170 Tilmicosin TIL 15 ASD03930 Fluconazole FLU 25 ASD00241 Ampicillin/sulbactam SAM 30 ASD01701 Cefoperazone CEP 30 ASD08211 Spectinomycin SPT 25 ASD09200 Tobramycin TOB 10 ASD03933 Fluconazole FLU 50 ASD00470 Apramycin APR 15 ASD01700 Cefoperazone CEP 75 ASD08200 Spectinomycin SPT 100 ASD09201 Tobramycin TOB 30 ASD03932 Fluconazole FLU 100 ASD00472 Apramycin APR 30 ASD01710 Cefoperazone/sulbactam CES 105 ASD08311 Spiramycin SP 10 ASD09310 Trimethoprim TMP 1.25 ASD03940 Flucytosine 5FC 1 ASD00500 Azithromycin AZM 15 ASD01810 Cefotaxime CTX 5 ASD08310 Spiramycin SP 30 ASD09303 Trimethoprim TMP 2.5 ASD04450 Griseofulvin GRS 10 ASD00501 Azithromycin AZM 30 ASD01801 Cefotaxime CTX 10 ASD08300 Spiramycin SP 100 ASD09300 Trimethoprim TMP 5 ASD04670 Itraconazole ITR 10 ASD00505 Azlocillin AZL 30 ASD01800 Cefotaxime CTX 30 ASD08400 Streptomycin S 10 ASD09301 Trimethoprim TMP 10 ASD04671 Itraconazole ITR 50 ASD00600 Azlocillin AZL 75 ASD01822 Cefotaxime/boronic acid CTX/BA 430 ASD08411 Streptomycin S 25 ASD09311 Trimethoprim TMP 25 ASD04750 Ketoconazole KTC 10 ASD00705 Aztreonam ATM 10 ASD01821 Cefotaxime/clavulanic acid CTC 15 ASD08410 Streptomycin S 300 ASD09302 Trimethoprim TMP 30 ASD04751 Ketoconazole KTC 50 ASD00700 Aztreonam ATM 30 ASD01820 Cefotaxime/clavulanic acid CTC 40 ASD08412 Streptomycin S 500 ASD09313 Trimethoprim/sulfadiazine TS 30 ASD05630 Miconazole MCZ 10 B ASD01823 Cefotaxime/Cloxacillin CEX 780 ASD08430 Sulfadiazine SD 100 ASD09320 Trimethoprim/ sulphamethoxazole SXT 25 ASD05632 Miconazole MCZ 30 ASD00810 Bacitracin B 0.04 U ASD01824 Cefotaxime/sulbactam CTS 40 ASD08431 Sulfadiazine SD 300 ASD09339 Triple sulphonamides S3 250 ASD05631 Miconazole MCZ 50 ASD00800 Bacitracin B 10 U ASD01830 Cefotaxime/tazobactam TCX 40 ASD08460 Sulfathiazole STZ 300 ASD09340 Triple sulphonamides S3 300 ASD06690 Nystatin NY 100 U ASD00850 Boronic acid APB 250 ASD01840 Cefotetan CTT 30 ASD08510 Sulfisoxazole ST 30 ASD09341 Triple sulphonamides S3 1000 ASD07720 Posaconazole POS 5 ASD00851 Boronic acid APB 300 ASD01901 Cefoxitin FOX 10 ASD08511 Sulfisoxazole ST 250 ASD09345 Trovafloxacin TRV 10 ASD08850 Terbinafine TRB 30 ASD00852 Boronic acid APB 400 ASD01900 Cefoxitin FOX 30 ASD08500 Sulfisoxazole ST 300 ASD09350 Tulathromycin TUL 30 ASD09500 Voriconazole VOR 1 C ASD08602 Sulphamethoxazole SMZ 25 ASD09360 Tylosin TY 15 ASD00905 Carbenicillin PY 10 PS-TR-48 ASD09370 Tylosin TY 30 Authorized Distributor ASD00910 Carbenicillin PY 25 ASD09380 Tylosin TY 60 ASD00900 Carbenicillin PY 100 V BIOANALYSE LTD. ASD01001 Cefaclor CEC 10 Factory: lvedik OSB. 1333. Cadde, ASD09410 Vancomycin VA 5 1377. Sokak, No: 5, Yenimahalle – Ankara / TURKEY ASD01000 Cefaclor CEC 30 Phone: +90 312 395 88 70 (pbx) • Fax: +90 312 395 88 66 ASD01100 Cefadroxil CFR 30 E-mail: [email protected] • www.bioanalyse.com 5/6 1/6 ANTIMICROBIAL SUSCEPTIBILITY TESTING DISCS (ASTD) PRODUCT LIST 2020 PRODUCT LIST 2020/01 PRODUCT LIST 2020/01 Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg Catalog No. Antimicrobial Agent Symbol mcg ASD01902 Cefoxitin/ cloxacillin CFX 30 ASD02810 Chloramphenicol C 5 ASD03475 Ertapenem/boranic acid ETP/BA2 310 ASD04520 Imipenem/cilastatin IMC 20 ASD05425 Meropenem/EDTA MEH 930 ASD06610 Novobiocin NV 5 ASD01910 Cefoxitin/boronic acid FOX/BA 430 ASD02820 Chloramphenicol C 10 ASD03660 Ertapenem/cloxacillin ETX 760 ASD04555 Imipenem/EDTA IEL 292 ASD05430 Methicillin ME 5 ASD06601 Novobiocin NV 10 ASD01940 Cefpirome CPO 30 ASD02800 Chloramphenicol C 30 ASD03471 Ertapenem/EDTA EEL 292 ASD04550 Imipenem/EDTA IEH 750 ASD05440 Methicillin ME 10 ASD06600 Novobiocin NV 30 ASD01960 Cefpodoxime CPD 10 ASD02801 Chloramphenicol C 50 ASD03474 Ertapenem/EDTA EEH 750 ASD04560 Imipenem/EDTA IPE 10 ASD05441 Methicillin ME 30 O ASD01965 Cefpodoxime CPD 30 ASD02840 Chlortetracycline CHT 30 ASD03800 Erythromycin E 5 ASD04600 Isepamicin ISP 30 ASD05512 Metronidazole MET 2.5 ASD07270 O129 O1/129 10 ASD01961 Cefpodoxime/clavulanic acid CPC 11 ASD03010 Ciprofloxacin CIP 1 ASD03801 Erythromycin E 10 ASD04650 Isoniazid INH 1 ASD05511 Metronidazole MET 4 ASD07271 O129 O2/129 150 ASD01966 Cefpodoxime/clavulanic acid CPC 40 ASD03000 Ciprofloxacin CIP 5 ASD03700 Erythromycin E 15 ASD04651 Isoniazid INH 5 ASD05500 Metronidazole MET 5 ASD06711 Ofloxacin OFX 2 ASD02000 Cefprozil CPR 30 ASD03020 Ciprofloxacin CIP 10 ASD03802 Erythromycin E 30 K ASD05513 Metronidazole MET 10 ASD06700 Ofloxacin OFX 5 ASD02050 Cefsulodin CFS 30 ASD03001 Ciprofloxacin CIP 30 ASD03804 Erythromycin E 60 ASD04701 Kanamycin K 2 ASD05515 Metronidazole MET 30 ASD06710 Ofloxacin OFX 10 ASD02060 Ceftaroline CPT 5 ASD03030 Ciprofloxacin CIP 50 F ASD04710 Kanamycin K 5 ASD05510 Metronidazole MET 50 ASD06800 Oleandomycin OL 15 ASD02101 Ceftazidime CAZ 10 ASD03102 Clarithromycin CLR 2 ASD03750 Fleroxacin FLE 5 ASD04700 Kanamycin K 30 ASD05514 Metronidazole MET 80 ASD06850 ONPG O/NPG --- ASD02100 Ceftazidime CAZ 30 ASD03101 Clarithromycin CLR 5 ASD03870 Florfenicol FFC 30 ASD04730 Kanamycin K 50 ASD05601 Mezlocillin MEZ 30 ASD06900 Optochin OP 5 ASD02112 Ceftazidime/Avibactam CZA 14 ASD03100 Clarithromycin CLR 15 ASD03900 Flucloxacillin FL 5 ASD04720 Kanamycin K 1000 ASD05600 Mezlocillin MEZ 75 ASD07000 Oxolinic acid OA 2 ASD02105 Ceftazidime/boronic acid CAZ/BA 430 ASD03310 Clindamycin DA 2 ASD03950 Flumequine FLM 30 ASD04732 Kanamycin/cephalexin KCL 45 ASD05710 Minocycline MI 25 ASD07010 Oxolinic acid OA 10 ASD02111 Ceftazidime/clavulanic acid CZC 20 ASD03120 Clindamycin DA 10 ASD04011 Fosfomycin FF 30 L ASD05700 Minocycline MI 30 ASD07100 Oxacillin OX 1 ASD02110 Ceftazidime/clavulanic acid CZC 40 ASD03121 Clindamycin DA 15 ASD04000 Fosfomycin FF 50 ASD04801 Levofloxacin LEV 1 ASD05740 Moxalactam MOX 30 ASD07110 Oxacillin OX 5 ASD02115 Ceftazidime/cloxacillin CZX 780 ASD03200 Cloxacillin CX 1 ASD04010 Fosfomycin FF 200 ASD04800 Levofloxacin LEV 5 ASD05801 Moxifloxacin MXF 1 ASD07112 Oxacillin OX 10 ASD02120 Ceftazidime/tazobactam TCA 40 ASD03210 Cloxacillin CX 5 ASD04050 Framycetin FM 100 ASD04802
Load more

Recommended publications
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Antibiotic Resistance Pattern to Different Isolates in Al-Hillah City, Iraq
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by International Institute for Science, Technology and Education (IISTE): E-Journals Journal of Natural Sciences Research www.iiste.org ISSN 2224-3186 (Paper) ISSN 2225-0921 (Online) Vo l.3, No.3, 2013 Pseudomonas aeruginosa: Antibiotic resistance pattern to different isolates in Al-Hillah city, Iraq Ali Hussein Al-Marzoqi1* (Corresponding author), and Zahraa Mohammad Al Taee2 1. College of Science for women, Babylon University, PO box 435, Al-Hillah city, Babylon, Iraq. Tel: 009647710336121 E-mail: [email protected] 2. College of Science, Babylon University * E-mail of the corresponding author: [email protected] Abstract Aim: Pseudomonas aeruginosa (Ps. aeruginosa) considered as most important bacteria which can isolated from various kinds of infection. This study tries to survey the infections caused by Ps. aeruginosa especially medical and surgical care units and try to reveal the antimicrobial agents susceptibility against Ps. aeruginosa. Material and Method: This study was conducted during September 2012 to February 2013. During this period total of 285 samples were tested and showed growth of bacteria. The isolates of Pseudomonas aeruginosa were selected on the basis of their growth on Nutrient agar pigmented and non-pigmented colonies with oxidase positive and on routine MacConkey medium which showed lactose Non-fermenting pale colonies. Antimicrobial susceptibility of all the isolates was performed using disc-diffusion (Modified-Kirby Baur method) according to CLSIs guidelines. Result: In present study, maximum isolates of Ps. aeruginosa isolated from various samples. The isolates were obtained from different clinical specimens, including pus, urine, respiratory fluids, blood, tissue, and genitalia.
    [Show full text]
  • Progress in Pharmacokinetics and Pharmacodynamics - I
    274 Abstracts Progress in pharmacokinetics and pharmacodynamics - I P1022 Pharmacokinetics of telithromycin in plasma and was higher in young women than in young men (21% difference), soft tissue after single-dose administration in healthy volunteers with only a 4% difference between elderly women and men. At the target clinical dose of 100 mg load infused over 30–60 min fol- R. Gattringer, F. Traunmueller, E. Urbauer, M. Zeitlinger, lowed by 50 mg q12h, Cmax and AUCss (mean Æ SD) were M. Mueller, C. Joukhadar 621 Æ 93 ng/mL and 3069 Æ 381 ng h/mL, respectively. Vienna, A Objectives: Telithromycin was described to reach high concentra- Dose (mg), with MD given q 12h tions levels in inflammatory fluid, in bronchopulmonary tissues and in tonsillar tissue. Because of these data telithromycin is spe- Pk parameter 12.5 25 50 75 100 200 300 culated to be a new option in the therapy of skin and soft tissue infections. To determine the concentration of telithromycin in the SD CLt 0.29 Æ 0.20 0.20 Æ 0.10 0.28 Æ 0.04 0.29 Æ 0.04 0.30 Æ 0.08 0.23 Æ 0.04 0.25 Æ 0.03 interstitial space fluid, the pharmacokinetics of this new antibiotic (L/hr/kg) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 57) (n ¼ 24) (n ¼ 12) were assessed after single dose administration in young healthy MD CLt ÁÁÁ 0.20 Æ 0.04 0.20 Æ 0.02 ÁÁÁ 0.24 Æ 0.045 ÁÁÁ ÁÁÁ (L/hr/kg) (n ¼ 5) (n ¼ 5) (n ¼ 3) volunteers by the use of microdialysis.
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • The Antibiotics Composition Comprising Beta-Lactam
    (19) & (11) EP 2 062 581 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 31/545 (2006.01) A61K 31/546 (2006.01) A61K 31/43 (2006.01) A61K 31/431 (2006.01) (2006.01) (2006.01) (21) Application number: 07785338.0 A61K 31/424 A61K 31/7036 A61K 47/18 (2006.01) A61K 47/12 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.08.2007 A61K 47/02 A61K 47/04 A61K 9/08 (2006.01) A61K 9/19 (2006.01) A61K 9/72 (2006.01) A61P 31/04 (2006.01) A61P 31/00 (2006.01) (86) International application number: PCT/CN2007/002438 (87) International publication number: WO 2008/025226 (06.03.2008 Gazette 2008/10) (84) Designated Contracting States: (71) Applicant: Tianjin Hemey Bio-Tech Co., Ltd. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tianjin 300457 (CN) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: ZHANG, Hesheng Designated Extension States: Tianjin 300457 (CN) AL BA HR MK RS (74) Representative: Hryszkiewicz, Danuta et al (30) Priority: 25.08.2006 CN 200610015437 Kancelaria Patentowa ul. Jana z Kolna 38 PL-75-204 Koszalin (PL) (54) THE ANTIBIOTICS COMPOSITION COMPRISING BETA-LACTAM ANTIBIOTICS AND IONIC CHELATING AGENTS (57) The antibiotics composition comprising at least tors and buffers simultaneously. The composition can be one of beta-lactam antibiotics and at least one of ionic formulated with at least one of aminoglycoside antibiotics chelating agents used for inhibiting particulate formation, into solution for controlling microbial infection in a con- further comprising at least one of beta-lactamase inhib- tainer.
    [Show full text]
  • List Item Assessment Report for Zinacef
    10 September 2012 EMA/CHMP/633654/2012 Assessment report for Zinacef and associated names Pursuant to Article 30 of Directive 2001/83/EC INN : cefuroxime (cefuroxime sodium) Procedure no: EMEA/H/A-30/1158 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Background information on the procedure .............................................. 3 1.1. Background information on the basis of the grounds for referral ................................. 3 2.1. Introduction......................................................................................................... 3 2.2. Critical Evaluation ................................................................................................ 4 Section 4.1 - Therapeutic indications ............................................................................. 4 Section 4.2 - Posology and method of administration .................................................... 30 Section 4.3 - Contraindications ................................................................................... 33 Section 4.4 - Special
    [Show full text]
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
    [Show full text]
  • The Antibiotics Composition Comprising Aminoglycoside Antibiotics
    (19) & (11) EP 2 062 585 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 31/7036 (2006.01) A61K 47/18 (2006.01) A61K 47/12 (2006.01) A61K 47/02 (2006.01) (2006.01) (2006.01) (21) Application number: 07785340.6 A61K 47/04 A61K 9/08 A61K 9/19 (2006.01) A61P 31/04 (2006.01) (2006.01) (22) Date of filing: 14.08.2007 A61P 31/00 (86) International application number: PCT/CN2007/002440 (87) International publication number: WO 2008/025227 (06.03.2008 Gazette 2008/10) (84) Designated Contracting States: (71) Applicant: Tianjin Hemey Bio-Tech Co., Ltd. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tianjin 300457 (CN) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: ZHANG, Hesheng Designated Extension States: Tianjin 300457 (CN) AL BA HR MK RS (74) Representative: Hryszkiewicz, Danuta et al (30) Priority: 25.08.2006 CN 200610015439 Kancelaria Patentowa ul. Jana z Kolna 38 PL-75-204 Koszalin (PL) (54) THE ANTIBIOTICS COMPOSITION COMPRISING AMINOGLYCOSIDE ANTIBIOTICS (57) The antibiotics composition comprising at least of beta-lactam antibiotics, or combined with at least one one of aminoglycoside antibiotics and at least one of ionic of beta-lactam antibiotics and at least one of beta-lacta- chelating agents used for inhibiting particulate formation, mase inhibitors into solutions for controlling microbial in- or at least one of buffers, or at least one of ionic chelating fection in a container.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Antibiotic Classes
    Penicillins Aminoglycosides Generic Brand Name Generic Brand Name Amoxicillin Amoxil, Polymox, Trimox, Wymox Amikacin Amikin Ampicillin Omnipen, Polycillin, Polycillin-N, Gentamicin Garamycin, G-Mycin, Jenamicin Principen, Totacillin, Unasyn Kanamycin Kantrex Bacampicillin Spectrobid Neomycin Mycifradin, Myciguent Carbenicillin Geocillin, Geopen Netilmicin Netromycin Cloxacillin Cloxapen Paromomycin Dicloxacillin Dynapen, Dycill, Pathocil Streptomycin Flucloxacillin Flopen, Floxapen, Staphcillin Tobramycin Nebcin Mezlocillin Mezlin Nafcillin Nafcil, Nallpen, Unipen Quinolones Oxacillin Bactocill, Prostaphlin Generic Brand Name Penicillin G Bicillin L-A, First Generation Crysticillin 300 A.S., Pentids, Flumequine Flubactin Permapen, Pfizerpen, Pfizerpen- Nalidixic acid NegGam, Wintomylon AS, Wycillin Oxolinic acid Uroxin Penicillin V Beepen-VK, Betapen-VK, Piromidic acid Panacid Ledercillin VK, V-Cillin K Pipemidic acid Dolcol Piperacillin Pipracil, Zosyn Rosoxacin Eradacil Pivampicillin Second Generation Pivmecillinam Ciprofloxacin Cipro, Cipro XR, Ciprobay, Ciproxin Ticarcillin Ticar Enoxacin Enroxil, Penetrex Lomefloxacin Maxaquin Monobactams Nadifloxacin Acuatim, Nadoxin, Nadixa Generic Brand Name Norfloxacin Lexinor, Noroxin, Quinabic, Aztreonam Azactam, Cayston Janacin Ofloxacin Floxin, Oxaldin, Tarivid Carbapenems Pefloxacin Peflacine Generic Brand Name Rufloxacin Uroflox Imipenem, Primaxin Third Generation Imipenem/cilastatin Balofloxacin Baloxin Doripenem Doribax Gatifloxacin Tequin, Zymar Meropenem Merrem Grepafloxacin Raxar Ertapenem
    [Show full text]